Lilly India enters the autoimmune segment with Olumiant™

Lilly India enters the autoimmune segment with Olumiant™

Chennai, October 25, 2018Eli Lilly and Company (India) Pvt. Ltd. (“Lilly India”) announced the launch of Olumiant™(baricitinib). This announcement marks the company’s entry into the autoimmune segment in India. Olumiant™ (baricitinib) is a once-daily oral medication for the treatment of adults with moderate-to-severe active Rheumatoid Arthritis who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Olumiant™ may be used as monotherapy or in combination with methotrexate. Olumiant™ will be available in India starting October 2018 in 4mg and 2mg dosage forms. Olumiant™ is approved in more than 50 countries across the world.

Despite the multiple options available for Rheumatoid Arthritis, there still exists an unmet need. More than half of the patients with moderate-to-severe Rheumatoid Arthritis do not experience remission through conventional DMARDs.

Speaking on the treatment for rheumatoid arthritis, Dr. VV Kaushik, Rheumatologist, Arthritis and Rheumatism Center, Chennai said, “Despite significant advances in the range of effective therapies over the decade, very significant patients’ needs remain. In my clinical experience, I continue to see patients who experience debilitating symptoms and are often unable to meet their treatment goals. The approval for Olumiant provides doctors and patients an important additional treatment option to support patients in their journey with RA .”  

In clinical studies, Olumiant™ has demonstrated statistically significant improvements in a number of outcome measures including patient reported outcomes at various time points with rapid onset of action and sustained efficacy as well as superiority to standard of care at ACR* 20 and DAS* 28 at 12 weeks.

Luca Visini, Managing Director, Eli Lilly and Company India said, “Lilly India is excited to announce the introduction of its innovative therapy for patients living with Rheumatoid Arthritis. It is an announcement that builds on our heritage and commitment to India, a 25 years strong legacy of making life better and addressing the unmet needs of patients living with chronic diseases.”

He added, “People with Rheumatoid Arthritis continue to struggle with the debilitating effects of the disease, endure pain and do not achieve disease management goals. This can lead to long-term joint damage and even disability. Olumiant™ is an effective, advanced once-daily oral treatment option for people suffering from Rheumatoid Arthritis who have not responded well to conventional DMARDs. In clinical trials, Olumiant™ has proven efficacy and demonstrated rapid and significant improvement in patient related outcomes such as pain, fatigue and joint stiffness. It is important for patients with Rheumatoid Arthritis to have multiple treatment options available to best suit their disease characteristics and experience.”